Page last updated: 2024-12-06

fr 109615

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cispentacin: structure given in first source; isolated from Bacillus cereus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID73305
CHEMBL ID1191824
SCHEMBL ID85607
MeSH IDM0180326

Synonyms (60)

Synonym
y1e02l9hc2 ,
cispentacin, (-)-
unii-y1e02l9hc2
(+/-)-cispentacin
(+/-)-2-aminocyclopentane-carboxylic acid
(-)-cispentacin
cis-(1r,2s)-2-aminocyclopentane-1-carboxylic acid
(-)-(1r,2s)-cispentacin
fr 109615
antibiotic fr 109615
(1r-cis)-2-aminocyclopentanecarboxylic acid
cyclopentanecarboxylic acid, 2-amino-, (1r,2s)-
cyclopentanecarboxylic acid, 2-amino-, (1r-cis)-
2-aminocyclopentane-carboxylic acid (1 r,2 s)-form
(1r,2s)-2-aminocyclopentanecarboxylic acid
122672-46-2
cispentacin
(-)-cis-2-acpc
37910-65-9
(1r,2s)-2-aminocyclopentane-1-carboxylic acid
[(1r,2s)-2-aminocyclopentane-1-carboxylic acid]
bdbm50339908
chembl1191824 ,
cis-pentacin
cis-2-amino-1-cyclopentanecarboxylic acid
AKOS006237128
(1r,2s)-2-amino-cyclopentanecarboxylic acid
AKOS015854163
racemic cis-2-aminocyclopentanecarboxylic acid
cis-2-amino-1-cyclopentane-carboxylic acid
cis-(+/-)-2-amino-cyclopentanecarboxylic acid
SCHEMBL85607
2-aminocyclopentanecarboxylic acid, (z)-
cyclopentanecarboxylic acid, 2-amino-, cis-
J-500322
(1r,2s)-cis-2-aminocyclopentanecarboxylic acid
cis-2-amino-1-cyclopentane carboxylic acid
(2s),(1r)-2-amino-cyclopentanecarboxylic acid
cispentacin, (+/-)-
fr-109615
9ZJP849D4I ,
cispentacin, (-)-(1r,2s)-
rel-(1r,2s)-2-aminocyclopentanecarboxylic acid
cyclopentanecarboxylic acid, 2-amino-, (1r,2s)-rel-
fr-109615, cis-(-)-
fr-109615, cis-(+/-)-
fr-109615, (+/-)-
J-520067
TS-7177
mfcd00882461
cis-2-amino-cyclopentanecarboxylic acid
(1r,2s)-cis-2-amino-cyclopentane carboxylic acid
unii-9zjp849d4i
cis-2-amino-1-cyclopentanecarboxylic acid relative stereochemistry
DTXSID40924231
F12971
AMY21145
CS-0131294
EN300-159750
cis-2-amino-1-cyclopentanecarboxylicacid

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"Chronic dosing with the glycine partial NMDA agonist, 1-aminocyclopropanecarboxylic acid (ACPC) elicited an altered allosteric regulation of cortical NMDA receptor binding."( Chronic dosing with 1-aminocyclopropanecarboxylic acid, a glycine partial agonist, modulates NMDA inhibition of muscarinic-coupled PI hydrolysis in rat cortical slices.
Boje, KM; Lakhman, SS, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
cytosolL-cysteine:1D-myo-inositol 2-amino-2-deoxy-alpha-D-glucopyranoside ligaseMycobacterium tuberculosis H37Rv
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID553542Antifungal activity against Saccharomyces cerevisiae ADCDR2 expressing Candida albicans CDR2 efflux pump in YNBG medium containing 1 mg/ml 1-glutamate after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID590639Inhibition of Mycobacterium tuberculosis recombinant MBP-tagged MshC assessed as formation of fluorescently labeled Cys-GlcN-Ins by HPLC2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Susceptibility and mode of binding of the Mycobacterium tuberculosis cysteinyl transferase mycothiol ligase to tRNA synthetase inhibitors.
AID553516Drug uptake in Saccharomyces cerevisiae AD12345678 at 200 uM pretreated for 10 mins measured after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553848Antifungal activity against Saccharomyces cerevisiae AD12345678 in YNPG medium containing 1 mg/ml 1-glutamate after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553541Antifungal activity against Saccharomyces cerevisiae ADCDR1 expressing Candida albicans CDR1 efflux pump in YNBG medium containing 1 mg/ml 1-glutamate after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553847Antifungal activity against wild type Saccharomyces cerevisiae ATCC 9763 in YNPG medium containing 1 mg/ml 1-glutamate after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553853Antifungal activity against fluconazole sensitive Candida albicans isolate Gu4 in RPMI-1640 buffered medium after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553537Drug extrusion in Saccharomyces cerevisiae ADCDR1 expressing Candida albicans CDR1 efflux pump reenergized with glucose at pH 6.0 assessed as fluorescamine-compound conjugate level after 30 mins2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553852Antifungal activity against wild type Candida albicans 10261 in RPMI-1640 buffered medium after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553535Drug accumulation in Saccharomyces cerevisiae ADCDR1 expressing Candida albicans CDR1 efflux pump reenergized with glucose at pH 6.0 assessed as intracellular accumulation after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553856Antifungal activity against fluconazole resistant Candida albicans isolate B4 overexpressing MDR1 in RPMI-1640 buffered medium after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553539Antifungal activity against wild type Saccharomyces cerevisiae ATCC 9763 in YNBG medium containing 1 mg/ml 1-glutamate after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553855Antifungal activity against fluconazole sensitive Candida albicans isolate B3 in RPMI-1640 buffered medium after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553854Antifungal activity against fluconazole resistant Candida albicans isolate Gu5 overexpressing CDR1 and CDR2 in RPMI-1640 buffered medium after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553534Drug accumulation in Saccharomyces cerevisiae AD12345678 reenergized with glucose at pH 6.0 assessed as intracellular accumulation after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553520Drug uptake in Saccharomyces cerevisiae ADCDR2 expressing Candida albicans CDR2 efflux pump at 200 uM pretreated for 10 mins measured after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553540Antifungal activity against Saccharomyces cerevisiae AD12345678 in YNBG medium containing 1 mg/ml 1-glutamate after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553850Antifungal activity against Saccharomyces cerevisiae ADCDR2 expressing Candida albicans CDR2 efflux pump in YNPG medium containing 1 mg/ml 1-glutamate after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553518Drug uptake in Saccharomyces cerevisiae ADCDR1 expressing Candida albicans CDR1 efflux pump at 200 uM pretreated for 10 mins measured after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553543Antifungal activity against Saccharomyces cerevisiae ADMDR1 expressing Candida albicans MDR1 efflux pump in YNBG medium containing 1 mg/ml 1-glutamate after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553851Antifungal activity against Saccharomyces cerevisiae ADMDR1 expressing Candida albicans MDR1 efflux pump in YNPG medium containing 1 mg/ml 1-glutamate after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553538Drug extrusion in Saccharomyces cerevisiae ADCDR2 expressing Candida albicans CDR2 efflux pump reenergized with glucose at pH 6.0 assessed as fluorescamine-compound conjugate level after 30 mins2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553536Drug accumulation in Saccharomyces cerevisiae ADCDR2 expressing Candida albicans CDR2 efflux pump reenergized with glucose at pH 6.0 after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553849Antifungal activity against Saccharomyces cerevisiae ADCDR1 expressing Candida albicans CDR1 efflux pump in YNPG medium containing 1 mg/ml 1-glutamate after 24 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
AID553522Drug uptake in Saccharomyces cerevisiae ADMDR1 expressing Candida albicans MDR1 efflux pump at 200 uM pretreated for 10 mins measured after 60 mins by fluorescamine staining2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (46)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (4.35)18.7374
1990's14 (30.43)18.2507
2000's18 (39.13)29.6817
2010's10 (21.74)24.3611
2020's2 (4.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.32 (24.57)
Research Supply Index3.89 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.13%)5.53%
Reviews2 (4.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other44 (93.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]